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Full-thickness burn and other types of deep skin loss will result in scar formation. For at least partial replacement of the lost dermal
layer, there are several options to use biotechnologically derived extracellular matrix components or tissue scaﬀolds of cadaver skin
origin. In a survey, we have collected data on 18 pts who have previously received acellular dermal implant Alloderm. The age of
these patients at the injury varied between 16 months and 84 years. The average area of the implants was 185 cm2. Among those,
15 implant sites of 14 patients were assessed at an average of 50 months after surgery. The scar function was assessed by using the
modified Vancouver Scar Scale. We have found that the overall scar quality and function was significantly better over the implanted
areas than over the surrounding skin. Also these areas received a better score for scar height and pliability. Our findings suggest that
acellular dermal implants are especially useful tools in the treatment of full-thickness burns as well as postburn scar contractures.
1. Introduction
Once the dermis of the injured skin is lost due to full-
thickness burn, it will either be replaced by scar that
originates from granulation tissue and epithelized from the
wound edges, or skin grafting will close the wound. Neither
the scar tissue, nor the patchy dermal residual islands of
dermal papillae provided by the split-thickness skin graft
(STSG)will result in a continuous healthy dermal layer to the
wound site. The quality and function of dermal connective
tissue and the amount and orientation of dermal elastic fibers
have great impact on postinjury skin quality. The typical
scar tissue is characterized by sparse elastic fibers and newly
formed collagen bundles in random orientation. There are
several methods available that are designed to improve the
qualities of the dermal wound bed, while some of these
methods aim to provide dermal tissue for replacement.
Harvesting thicker grafts will enormously increase donor site
morbidity; full-thickness skin grafting has a strict limitation
of a mere few square cms. Donor site is often limited
and when applying the gold standard of wound closure,
autologous stsg, it has to be expanded to a ratio where
disfiguring scarring is inevitable. A widely used alternative is
to restore barrier function until definitive closure by applying
temporary coverage, preferably with biological dressings.
A large variety of methods are available ranging from
xenograft (frog’s membrane to porcine skin) to allogenic
tissue (e.g., placenta, frozen-, cryopreserved- or glycerol
preserved human skin). Risk of transmission of infectious
diseases is a theoretical drawback of these materials; despite
implementing tissue banking guidelines, this risk is relative
low. There is a range of bioengineered skin substitutes
available for the purpose of improving the quality of skin
in the area of dermal loss. These can either be applied
during tissue repair or after scar formation, as tools for
reconstructive surgery.
Due to the diversity of the commercially available
biotechnologically produced materials, it is rather diﬃcult to
compare their real value and usefulness, and there remains
some uncertainty regarding their eﬀectiveness. Some of
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these materials contain cells, some only cellular products,
characteristically in a rather complex manner. Clinically,
as it seems, the simple delivery of macromolecules, such
as collagen, in an unstructured manner (powder, cream,
gel, etc.) may not fulfill the many requirements of the
proliferative phase of wound healing. It is likely, that a 3-
dimensional structure is mandatory, eﬀectively provided by
an acellular natural dermal scaﬀold or a tissue-engineered
newly formed biological matrix. There remains a question
whether themore complex cellular products could deliver the
extra clinical advantage, that justifies the higher cost associ-
ated with their production. Besides the high price, challenges
in obtaining reimbursement, together with complicated
regulations and approval regarding the use of allogeneic cells
make the future of these products uncertain [1]. The name
and origin of some of the most typical and important tissue-
engineered materials are summarized in Table 1 in the order
of their complexity and appearance on the market.
2. Acellular Preparations
MB-Collagen or Collagen-Klee (Medical Biomaterial Prod-
ucts GmbHNeustadt-Glewe, BRD), a resorbable, 5mm thick
collagen membrane made of porcine origin is an example of
the many collagen delivery devices on the market to promote
connective tissue proliferation during wound repair [2].
BGC Matrix (Brennen Medical Inc, St. Paul MN, USA)
consists of beta-Glucan, a complex carbohydrate isolated
from the cell wall of oats and a porcine collagen hydrocolloid
matrix combined in a multifilament mesh [3].
Promogran (Systagenix Wound Management Ltd., Gar-
grave, UK), in addition to its bovine collagen content,
also contains regenerated oxidized cellulose as an additional
source of substrate for binding to matrix metalloproteases
present in the chronic wounds. Substrate substitution aims
at the inactivation of ECM degrading enzymes and the
protection of naturally occurring growth factors. It is con-
cluded that protease-modulation by substrate substitution
acts synergistically with autologous growth factors in diabetic
foot ulcers [4].
Biostep/Biostep Ag Collagen Matrix Dressing (Smith &
Nephew Inc. St. Petersburg, FL USA) provides its porcine
collagen content considerable antimicrobial activity with the
combination of Silver ions (company information).
Matriderm (Dr. Suwelack Skin & Health Care AG,
Billerbeck, BRD) is a three-dimensional matrix consisting
of collagen and elastin, comparable to the structure of
human dermis. The sheets are used in a one-step procedure,
applied dry, possess unique hemostyptical characteristics,
and rehydrate “in loco” after grafting. When full-thickness
acute burn wounds are treated with STSG alone, and with the
use of Matriderm, the use of the device results in improved
scar (skin) formation [5].
Alloderm regenerative tissue matrix (LifeCell Co., The
Woodlands, TX USA) is a freeze-dried extracellular matrix
(ECM) tissue derived from cadaver skin, through a process
resulting in removal of all cellular components and residues.
The ECM has high hyaluronan and proteoglycan content,
while the scaﬀold retains its collagen and elastic fiber content
and structure, with an intact basement membrane. The
material is made from tissue bank skin and has a 2-year shelf
life. The acellular dermal implant Alloderm is available also
in a meshed version and has been advocated and approved
since 1995 for the management of acute burns in which
the dermis is severely damaged [6]. It allows the utilization
of ultra thin autograft skin, (0,1-0,2mm instead of 0,35–
0,5mm), strongly reducing donor site morbidity and soon
allowing for reharvesting the donor area. The product in fact
has received its FDA approval, as “banked human tissue” and
not as a “medical device” if used in an orthotopic way, that
is, as skin replacement. Probably it is the most widely used
product for dermal regeneration as of now.
The European version of Alloderm is called Glyaderm
acellular dermal collagen-elastin matrix. It is a dermal
substitute produced by the Euro Skin Bank (Beverwijk,
NL) and is based on the glycerol-preservation technique,
developed for producing allogenic temporary skin grafts for
burn treatment [7].
SureDerm (Hans Biomed Corp., Seoul, Korea) is another
similar product to Alloderm. It is made according to
AATB (American Association of Tissue Banks) guidelines in
South Korea, requiring less rehydration time (10 minutes
versus 20–40 minutes). Only limited scientific information
is available [8], but this relatively newcomer product has
both FDA and CE approval, allowing to gain its share of the
market.
Integra (Integra LifeSciences Co., Plainsboro, NJ USA)
dermal regeneration template consists of two layers; a porous
chondroitin 6 sulphate glucosaminoglycane (GAG) and
bovine collagen-based dermal analogue, which integrates
with the patient’s own cells and a supporting epidermal
silicone sheet. The product besides promoting and regulating
dermal development also provides a massive temporary
cover of the wound area; the protective layer, later as the
wound heals, gets peeled oﬀ. A very thin autograft is then
grafted onto the neo-dermis. Integra is primarily indicated
for the postexcisional treatment of full-thickness or deep
partial-thickness burns and similar tissue defects. A relatively
high incidence rate of infectious complications follows its
application, but its frequency can be reduced bymore careful
timing, that is, earlier application [9].
3. Cell-Containing Devices
TransCyte, formerly Dermagraft TC (Advanced BioHeal-
ing Inc, Westport, CT USA) is a temporary, biosynthetic
covering material composed of a semipermeable silicone
membrane and human fibroblast cells of newborn foreskin
origin cultured on a porcine collagen coated nylon mesh.
During the 17 days manufacturing cycle in a so-called
“bioreactor” the cellular products, fibronectin, tenascin, gly-
cosaminoglycans, growth factors reach high concentration.
The device is then frozen and stored at −70◦C until it is
used. Human application is possible, because the fibroblasts
reaching the wound surface are metabolically already inactive
and do not provoke immunological rejection [10]. It has
been indicated for use as a temporary covering for excised
burns prior to autografting. Another indication is to use it
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Table 1: Biotechnologically derived products designed to improve dermal wound repair.
Biotechnological device
Name Composition Manufacturer
Cellular
content
Ref. no
MB-Collagen/Collagen-
Klee
Porcine collagen
Medical Biomaterial Products GmbH
Neustadt-Glewe, BRD
no [2]
BGC Matrix Porcine collagen and beta-Glucan
Brennen Medical Inc, St. Paul MN,
USA
no [3]
Promogran
Bovine collagen, regenerated oxidized
cellulose
Systagenix Wound Management Ltd.,
Gargrave, UK
no [4]
Biostep/Biostep Ag
Collagen Matrix Dressing
Porcine collagen
Smith & Nephew Inc. St. Petersburg,
FL USA
no —
Matriderm Bovine collagen and elastin matrix
Dr. Suwelack Skin & Health Care AG,
Billerbeck, BRD
no [5]
Alloderm regenerative
tissue matrix
Freeze-dried ECM from cadaver skin LifeCell Co., The Woodlands, TX USA no [6]
Glyaderm dermal
replacement material
Dermal collagen-elastin matrix Euro Skin Bank, Beverwijk, NL no [7]
SureDerm Freeze-dried ECM from cadaver skin Hans Biomed Corp., Seoul, Korea no [8]
Integra dermal
regeneration template
Bovine collagen and GAG, with a
supporting epidermal silicone sheet
Integra LifeSciences Co., Plainsboro,
NJ USA
no [9]
TransCyte/Dermagraft TC
temporary, biosynthetic
wound cover
Porcine collagen coated nylon mesh
with human fibroblast and silicone
membrane
Advanced BioHealing Inc, Westport,
CT USA
yes [11]
Dermagraft
Biodegradable polyglactin mesh with
human fibroblast
Advanced BioHealing Inc, Westport,
CT USA
yes [12]
Apligraf/Graftskin living
skin equivalent
Bilayered structure bovine collagen
with human fibroblasts and human
keratinocytes
Organogenesis Inc., Canton, MA USA
and Novartis AG Basel, CH
yes [13]
OrCel cryopreserved
bilayered matrix
Bilayered structure bovine collagen
with human fibroblasts and human
keratinocytes
Forticell BioScience Inc., New York,
NY USA
yes [16]
StrataGraft Pathogen-free
human temporary allograft
Bilayered structure: non-bovine
collagen with human fibroblasts and
immortalized human keratinocytes
Stratatech Corporation, Madison, WI
USA
yes [17]
on donor sites or burns that do not require autografting, that
is, as a biological dressing material [11].
Dermagraft (Advanced BioHealing Inc, Westport, CT
USA) is similar to the previous device, but the scaﬀold is
a biodegradable polyglactin mesh seeded with allogeneic
neonatal fibroblasts. The fibroblasts proliferate and pro-
duce dermal collagen, growth factors, glycosaminoglycans
(GAGs), and fibronectin to restore the dermal bed, while
the mesh material is gradually absorbed. It is intended to
be used as a temporary covering to promote wound healing
via multiple applications of the device. The result of this
type of approach is second intention healing, one reason why
Dermagraft is primarily intended for diabetic foot ulcer [12].
Apligraf formerly Graftskin (Organogenesis Inc., Can-
ton, MA, USA and Novartis AG Basel, CH) is a bilayered
living skin equivalent composed of allogeneic fibroblasts and
type I bovine collagen as dermis and allogeneic neonatal
foreskin-derived keratinocytes as epidermis. It has a short
shelf-life of 5 days, so needs to be applied while “fresh”. It
is on the market since 1998 and is currently approved for
accelerating the closure of chronic wounds, diabetic foot,
and venous leg ulcer. Experimental application in excised
deep burn wounds combined with autografting was reported
by Waymack et al. [13]. Apligraf ’s DNA persisted in a
minority of patients only at 4 weeks after grafting in acute
partial-thickness wounds [14]. Its success in speeding the
healing of acute wounds appears to be related to other
factors than the persistence of donor DNA or basement
membrane restoration. For the treatment of deep chronic
wounds, the same manufacturer developed a monolayer
product, with live human fibroblasts in a collagen matrix,
without a keratinocyte layer [15], which is currently not
available. A further developed version of Apligraf aiming
to omit the use of xenogenic collagen and utilizing human
collagen produced de novo by the human fibroblasts is in
late-stage development (VCT01, company information).
OrCel (Forticell BioScience Inc., New York, NY USA)
is a cryopreserved bilayered matrix with fibroblasts and
keratinocytes cultured on type I. collagen 3D matrix. Its
FDA approval was obtained in 2001 for treatment of acute
surgical excisions, such as contracture release sites and donor
sites in epidermolysis bullosa (EB) patients undergoing hand
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reconstruction surgery and burn surgery donor sites [16].
Due to a long period of in vitro expansion, the constiuent
cells cease to express significant levels of HLA-II antigens
and, upon application to a wound bed, are apparently not
immediately recognized by the recipient’s immune system.
StrataGraft (Stratatech Corporation, Madison, WI USA)
is a bilayered skin substitute providing a dermis and a
stratified, functional epidermis generated from a pathogen-
free, human keratinocyte progenitor cell line, Neonatal
Immortalized KeratinocyteS (NIKS). This new device has
functional performance comparable to cadaver allograft for
the temporary management of burns and other complex
skin defects before autografting [17]. The major advantage
is its full consistency and reproducibility and a resulting
additionally lower risk of disease transmission.
4. Long-Term Followup of Alloderm Grafts
An investigation was planned to study the beneficial eﬀect
of dermal replacement on the healing process. In authors’
country, Hungary, availability of products intended to
improve dermal repair is strictly limited. Not all of the
previously listed materials are available. In our facility for
burn treatment, we have been using Alloderm regenerative
tissue matrix over 10 years for burn patients with good
functional and cosmetic results. Besides Alloderm, authors
have personal experience with the use of Collagen-Klee,
Promogran, Integra, and Apligraf only. The indication of
both Promogran and Apligraf allows only treatment of
chronic wounds. Collagen-Klee and Integra were applied
only on few occasions by us with promising results. The
low number of cases however did not result in suﬃcient
data allowing comparison with our regularly used product,
Alloderm. In order to assess the long-term results of dermal
replacement, a study wasmade among our burn patients who
received this implant material.
5. Materials and Methods
We have reviewed the case documentation of 17 patients at
the Burn and Dermatosurgery Unit at the Department of
Dermatology, Medical and Health Science Center, University
of Debrecen, Debrecen, Hungary who were grafted with
a sandwich graft combining Alloderm regenerative tissue
matrix and thin autologous STSG. The operations took place
between the years 1996 and 2006 (Table 2). We carried out
18 operations at 17 pts whose average age was 33,7 (1,4–
84) years. There were two types of operations; “early” and
“late”. Early operation was regarded when the implantation
of Alloderm was executed before wound closure (n = 10),
with the intention to improve the quality of the resulting
burn scar. Late operations were scar revisions (n = 8) done
for release of contractures over a joint. The patients were
operated on the average 17,8 postburn day and at the average
5,62 months postburn in the two groups, respectively. The
majority of the patients had full-thickness burns, a small
percentage had deep partial-thickness/full-thickness mosaic
burns, the average TBSAwas 35% (15%–96%). Implantation
was always carried out in areas of full-thickness skin loss,
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Figure 1: Comparison of scar qualities of the Alloderm implant
sites and surrounding tissue by the modified Vancouver Burn Scar
Index (VBSI).
either burns or excised scars. During the operations, we
grafted 3140 cm2 s of the material, at an average of 185 cm2 s
(6–1050 cm2 s). Initially we adhered to the recommendation
of the manufacturer to regularly apply antibiotic solutions
to the dressing, later we changed our protocol to the use of
nanocrystalline silver dressings (Acticoat, Smith & Nephew
Wound Management, Hull UK) as a protective overlay and
administered no local antibiotics.
5.1. Determination of Scar Qualities. A representative area
of the dermal implant site was chosen, and its scar qualities
were determined by themodified Vancouver Burn Scar Index
(VBSI), described previously by Oliveira [18] upon four
criteria, not including pain and pruritus. A comparable
matching site of the surrounding burn scar was also chosen
that received no Alloderm implant previously, and its
scar qualities were also determined by the modified VBSI
(Figure 1).
5.2. Statistical Analysis. Results were expressed as means ±
SEM. Statistical significance between groups was determined
by Student’s t-test; P < .05 was considered as significant.
Error bars represent ±SEM.
6. Results
The Alloderm implantations were extensively photo-
documented, and records were made on the take-rate of
the sandwich grafts, which was found to be 99%. We have
seen no inflammatory reaction, no rejection, no infection,
and most importantly all of the implantations resulted in
soft pliable skin with acceptable cosmesis. Three of our
patients died shortly (bw. 15–40 days) after the operation,
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Table 2: List of patients grafted with a sandwich graft combining Alloderm regenerative tissue matrix and thin autologous split thickness
skin graft.
Age of pt. at
burn
Dermal replacement
Depth of burn TBSA %
Burn
mechanism
Age of scar at
control (mo)
Graft area
(cm2)
Type
Days after
burn
Months
after burn
(1) 6 early 30 (III) degree 96 flame exit 32
(2) 35 late 2 (III) degree, scar 25 scald 48 180
(3) 8 late 4 (III) degree, scar 20 contact 86 104
(4) 40 late 6 (III) degree, scar 15 scald 46 110
(5) 42 early 14 (III) degree 20 contact 14 200
(6) 42 early 3 (IIb-III) degree 25 contact 36 44
(7) 14 late 3 (III) degree, scar 65 electr + contact 85 130
(8) 28 early 4 (III) degree 18 contact 19 720
(9)
16
early 10 (III) degree
75
electr + contact 122 850
(10) late 4 (III) degree, scar electr + contact 118 200
(11) 1,8 late 22 (III) degree, scar 20 scald 34 30
(12) 1,4 early 16 (IIb-III) degree 15 scald 70 6
(13) 43 late 2 (III) degree, scar 19 scald 13 90
(14) 84 late 2 (III) degree, scar 35 flame exit 40
(15) 47 early 27 (III) degree 55 flame exit 110
(16) 49 early 25 (III) degree 25 contact 18 220
(17) 72 early 28 (III) degree 32 flame 36 45
(18) 43 early 21 (III) degree 39 contact 14
30
3140
Avg. 33.66 17,8 5,62 35 50,6 185
Table 3: Determination of scar qualities of the Alloderm implant sites and surrounding tissue by the modified Vancouver Burn Scar Index
(VBSI).
PIGM HEIGHT FLX VASC SUM PIGM HEIGHT FLX VASC SUM
(1) 1 1 1 0 3 1 2 1 0 4
(2) 1 1 1 0 3 1 2 1 0 4
(3) 2 0 1 0 3 2 2 3 0 7
(4) 2 0 0 0 2 2 1 1 0 4
(5) 1 1 1 0 3 2 1 4 0 7
(6) 1 0 0 0 1 2 1 1 0 4
(7) 0 0 1 0 1 2 2 4 0 8
(8) 2 1 1 0 4 2 2 4 2 10
(9) 1 0 0 0 1 2 1 1 0 4
(10) 3 1 1 0 5 3 2 3 0 8
(11) 1 2 1 1 5 1 1 1 1 4
(12) 1 0 0 0 1 1 1 1 0 3
(13) 1 0 0 0 1 1 1 1 0 3
(14) 2 0 1 1 4 3 0 2 1 6
(15) 2 0 1 1 4 3 0 2 1 6
Dermal replacement area Surrounding scarred skin
Abbreviations: PIGM: pigmentation, FLX: flexibility, VASC: vascularization, SUM: summary.
their grafts were also problem free. In order to determine the
long-term results of the interventions, we called the patients
to control in 2007. During the control, 14 patients with 15
operation sites were investigated. The average age of scar
at investigation was 50,6 months (14–122 months). Scar
qualities were determined by VBSI, both of a representative
area of the dermal implant site, and that of a chosen
comparable matching site of the surrounding burn scar,
that received no Alloderm implant previously. The VBSI
measurements of the sites are collected in Table 3.
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(a)
(b) (c) (d) (e)
Figure 2: Patient no. 3, 8-years-old male suﬀered 4 months earlier from full-thickness burn on 20% body surface area and had conservative
treatment (at another institution). (a) Upon admission: spontaneous rupture of scar that was causing severe axillary contracture. (b)
Intraoperative photograph after removal of scar tissue. Full axillary function following sandwich grafting with Alloderm and thin autologous
skin at (c) 3 months and (d) 7 years postoperatively. (e) No visible trace of previous harvesting of autograft skin can be seen at the donor site
on right thigh (picture taken at 7 years post-op.).
The examinations revealed uniformly better VBSI values
in the Alloderm implant group than in the control group.
The diﬀerences in color, thickness, and vascularization of
the skin at the dermal replacement site were not significant
when compared to control. Flexibility and overall scar quality
however were significantly better at the Alloderm implant
site than at the control area. In addition to the favorable
quality of scar (skin) at the site of dermal replacement, the
functional results were also excellent; all of the patients with
no exception, who were operated due to scar contracture,
regained their full joint movement.
7. Discussion
In an elegant series of nude mouse transplantation experi-
ments, Truong et al. [19] compared eﬀects of dermal substi-
tutes on wound healing. They experienced that human skin-
derived products, Alloderm and their similarly processed
own acellular dermal matrix produced the least contraction
and the thickest neodermis in the healed wounds, when
compared to control or synthetic dermal substitutes. The
application of processed acellular cadaver dermis has proven
extremely useful in the fields of burns and reconstructive
surgery and is gaining acceptance elsewhere, for various
oﬀ-label indications for example, in neurosurgery [20],
ophthalmic surgery [21], head and neck surgery [22, 23],
and in hernia repair [24]. Its application in extensive burns
provides the grafted area with functionally and esthetically
outstanding skin as a result. Despite being an additional layer
between the wound bed and epithelial cover, it does not hin-
der graft take. Possibly due to its intact ECM structure, the
repopulation by recipient cells, fibroblasts, endothelial cells,
and so forth, is extremely rapid. Clinically the STSG overlay
acts no diﬀerently than a simple skin graft, their color and
other vitality signs are identical. There is the added advantage
of the possibility of harvesting ultra thin (0,1-0,2mm thick)
skin for autografting, which dramatically reduces the trauma
of the donor area. The resulting neodermis is soft, pliable
resembling normal skin. In two early cases the Alloderm
containing sandwich graft was applied to the decorticated
bone of the scapula (unpublished case) and of the proximal
third of the tibia [25]. In both cases, a vital neodermis
was the result, that could be easily wrinkled and provided
protective support to the overlaying epidermis. Histological
examination revealed an inflammation-free neodermis, with
ample vascularization and abundant loose collagen fibrils
plus oligocellular elastic connective tissue. The epidermis
had normal structure and keratinisation, with apparent
cell proliferation (indicated by Ki67 mAb expression). The
Alloderm implant converted into a compact, functionally
and morphologically live neodermis as an interconnection
between the epidermal layer of the skin and the underlying
bony tissue [25]. In the opinion of the authors, the easy, one-
step procedure of Alloderm grafting with a simultaneous thin
STSG overlay is an ideal, minimally invasive procedure in
case of joint contractures, delivering in most cases superior
or comparable results to complicated skin or fasciocutaneous
flaps without the associated donor site morbidity.
Hereby, we present cases in which we have used this
implant during the surgery of acute burns as well as in the
treatment of postburn scar contractures. In our survey, we
have collected data on our patients with full-thickness burns
and scar contractures and assessed scar qualities compared to
that of their neighboring similarly treated but nonimplanted
burn scars. A total of 15 dermal replacement sites and 15
control sites were evaluated and compared. The applied VBSI
results confirmed our hypothesis, namely, the implantation
of acellular dermal implant makes a considerable impact on
the quality of the resulting scar, by making it softer and
more elastic than the surrounding tissue receiving no dermal
implant.
A major advantage of the technique is the reduction of
donor-site morbidity (Figure 2) due to the application of
very thin autologous skin required.
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